Igor Vkv / Shutterstock.com
Natalia Gulyaeva and Maria Sedykh of Hogan Lovells look at the main drivers of collaboration in the pharmaceutical sector and the legal issues to keep in mind when handling partnerships in Russia.
The life sciences industry has remained dynamic even in the years of economic downturn. Clearly, this high IQ industry is smart enough to adjust to the changing market conditions and to see the silver lining.
Russia has been called a “pharmerging” country along with China, India, Mexico, and other developing markets with large populations.
These countries were once considered the saviours of big pharma companies, given the immense patent cliff in the US and Europe. But over the last few years, the sales growth in such “pharmerging” markets has decreased.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at email@example.com.
If you have any technical issues please email tech support.
Natalia Gulyaeva, Maria Sedykh, Hogan Lovells, life sciences, pharmaceutical industry, research and development, R&D, CIS, PTO, patent,